pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 21·1 min read
save

Epic Systems sees senior leadership exits amid speculation of broader exodus

Jul 21, 2026·read at STAT ↗Negative

Epic Systems is experiencing notable executive turnover, highlighted by the recent departure of President Sumit Rana, who had been expected to succeed CEO Judy Faulkner.

Rana told a reporter last summer that he would “disappear if I want to” and that no single person should be essential to the company’s success, comments that now appear prescient amid his exit.

The STAT Health Tech newsletter also mentioned other industry moves, including a new CEO appointment at Nabla, but the focus remains on the potential ripple effects of the leadership changes at Epic.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Is there an exodus underway at Epic?”

read at STAT ↗
1,006 words · retrieved Jul 21
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOLBRISTOL MYERS SQUIBBBRISTOL MYERS SQUIBB CONOVONovo Nordisk Inc
drugs
Obesity
topics
GLP-1 receptor2Psychiatry & CNS2ObesityOphthalmology

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • May 12A year after Vertex’s big launch, pain drug research faces a pivotal momentBioPharma Dive
  • Jul 30Chutes & Ladders—Legend CEO departs without successor in placeFierce Biotech
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech
  • Jul 16Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunoBioSpace